AKBA - Akebia plans to resubmit vadadustat NDA by end of Q3
2023-08-24 10:15:14 ET
More on Akebia
- Akebia: 'Hold' Through Regulatory And Financial Hurdles
- Akebia Therapeutics: Take Profits Before Second Quarter Report
- Akebia Therapeutics: Buy This Undervalued Stock At Just 77% Of Revenue
- Akebia settles last patent lawsuit related to kidney disease therapy
- Seeking Alpha’s Quant Rating on Akebia
For further details see:
Akebia plans to resubmit vadadustat NDA by end of Q3